SCHEDULE: Deep Track Capital Discloses 6.78% Stake in Enanta Pharma

Deep Track Capital, LP and affiliated entities have reported a 6.78% beneficial ownership stake in Enanta Pharmaceuticals Inc. as of December 31, 2025.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively beneficially own 1,956,867 shares of Enanta Pharmaceuticals Inc. Common Stock.
• This represents 6.78% of the outstanding Common Stock.
• The beneficial ownership includes shared voting and dispositive power over all 1,956,867 shares.
• The percentage is calculated based on 28,862,601 shares outstanding as of November 4, 2025, as reported in the issuer's 10-K filed on November 19, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral disclosure of a significant ownership stake by an institutional investor, which is a routine regulatory filing without inherent positive or negative implications for company performance.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Deep Track Capital's significant stake in Enanta Pharmaceuticals, a biotechnology company, indicates a strategic investment in the pharmaceutical sector, often driven by potential drug pipeline developments or market positioning.

Stakeholder Impact

• The disclosure of a significant institutional investor holding 6.78% of the common stock may be viewed positively by other shareholders, signaling confidence in the company's prospects.
• The shared voting and dispositive power indicates a coordinated investment strategy among the reporting persons, potentially influencing future corporate actions or shareholder votes.

Key Dates

Keywords

Enanta Pharmaceuticals, Deep Track Capital, Beneficial Ownership, Schedule 13G, Biotechnology, Investment, Common Stock, Institutional Investor